Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines. This means that they use a completely new approach to fighting a specific disease. This is the conclusion reach by the authors of a new report by The Analysis Group commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), representing the country’s leading innovative biopharmaceutical research companies.
The report called The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.
The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies or antibody-drug conjugates.
Unique molecule-indication combinations
The analysis found that there are more than 4,000 projects ? defined as unique molecule-indication combinations ? in clinical development for oncology, 450 for cardiovascular disease and 700 for neurology, including 143 in Alzheimer’s disease, 67 in Parkinson’s disease and 29 in amyotrophic lateral sclerosis (ALS).
“We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to find treatments for the world’s biggest health care challenges,” said Stephen J. Ubl, president and CEO of PhRMA. “And as this new report underscores, we’re on the cusp of even more incredible breakthroughs that could further revolutionize how we prevent, treat and even cure disease for patients.”
The report also found that 822 projects in clinical development are designated by the U.S. Food and Drug Administration (FDA) as orphan drugs, which is critically important given only 5 percent of rare diseases have an approved medicine.
Last editorial review: July 19, 2017
Featured Image: Researcher in laboratory Courtesy: ? 2017 Fotolia. Used with permission.
Copyright ? 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.
